Jun 22, 2020
Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program
May 18, 2020
Sight Sciences Announces Positive Clinical Results from Randomized, Controlled Trial of TearCare for the Treatment of Dry Eye Disease
May 07, 2020
Bioclinica Announces Comprehensive COVID-19 Clinical Endpoint Adjudication Solution
Feb 18, 2020
The First Patient Included in Japan in Isofol's Phase 3 AGENT Study
Jan 24, 2020
The First Patient Included in Australia in Isofol's Phase 3 AGENT Study
Jan 22, 2020
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
Jan 21, 2020
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
Dec 12, 2019
Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
Dec 06, 2019
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
Nov 06, 2019
New Unpublished Clinical Trial Results Announced at VIVA19
Oct 18, 2019
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Sep 04, 2019
Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study
Jun 26, 2019
Ethical integrates Smart Redaction Technology to eAdjudication® Software for Clinical Endpoint Adjudication
Jun 25, 2019
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Jun 18, 2019
Signant Health Experts Share Benefit of Integrating Patient-centric Technology Solutions at Global Life Sciences Annual Forum DIA 2019
Jun 18, 2019
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
May 23, 2019
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
Dec 18, 2018
First Patient Enrolled in Isofol's Pivotal Phase 3 AGENT Study in 1st Line Metastatic Colorectal Cancer
Oct 16, 2018
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
Jun 05, 2018
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin